Savonix offers Savonix Mobile, a fully mobile cognitive assessment platform available on Android and iOS that delivers accessible, accurate and affordable assessments for healthcare providers, payers and researchers. The company leverages machine learning to gather insights linking cognition to biomarkers and diseases such as diabetes and dementia. Led by clinical neuropsychologists and digital health technology experts, Savonix supports diagnostic screening and treatment-planning workflows. The company plans to accelerate growth and market expansion in the US and Asia and to further develop and add features to its lead product to better assess, track and monitor cognitive health. Savonix also intends to build personalized treatment plans and expand cognitive datasets, including for non‑Caucasian populations. Financially, Savonix completed a $9.6M Series A extension, bringing the total round to $14.7M. Founded in 2015 and based in San Francisco, Savonix provides Savonix Mobile, a mobile cognitive assessment platform that gives healthcare providers, payers and patients a comprehensive view of critical domains of cognitive function. The platform enables clinicians to assess, track and understand a patient’s cognitive health and to build individualized treatment plans. Savonix plans to use new funding to scale its business into global markets, including Japan and China, and to develop additional partnerships with medical organizations. The company also intends to invest in its data science and product teams to enhance the offering. Financially, the business announced a $5.1M Series A that brought its total financing to $6.6M. In conjunction with the round, executives from investors will join Savonix’s board. Savonix is a San Francisco, CA-based developer of an evidence-based digital neuro-cognitive assessment and brain health platform. Led by Dr. Mylea Charvat, CEO and Founder, Savonix is building a mobile platform that enables end users to conduct a full clinically recognized cognitive assessment directly from their mobile device in half an hour. The platform also provides a suite of complementary tools intended to help individuals, employers, and healthcare and primary care physicians evaluate and leverage results to improve brain health. The company closed $1.5M in seed funding and plans to use the proceeds to hire new staff and to launch and scale its flagship assessment product. Savonix's offerings are positioned at the intersection of clinical assessment and consumer-accessible mobile health.

Total raised

$16M

Funding rounds

3

Latest round

Series A

Latest activity

Apr 2019